The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Hydrogen sulfide slows down progression of experimental Alzheimer’s disease by targeting multiple pathophysiological mechanisms
Open accessAbstract
It has been previously reported that brain hydrogen sulfide (H2S) synthesis is severely decreased in Alzheimer's disease (AD) patients, and plasma H2S levels are negatively correlated with the severity of AD. Here we extensively investigated whether treatment with a H2S donor and spa-waters rich in H2S induces neuroprotection and slows down progression of AD. Studies with sodium hydrosulfide (a H2S donor) and Tabiano's spa-water were carried out in three experimental models of AD. Short-term and long-term treatments with sodium hydrosulfide and/or Tabiano's spa-water significantly protected against impairment in learning and memory in rat models of AD induced by brain injection of β-amyloid1-40 (Aβ) or streptozotocin, and in an AD mouse model harboring human transgenes APPSwe, PS1M146V and tauP301L (3xTg-AD mice). The improvement in behavioral performance was associated with hippocampus was size of Aβ plaques and preservation of the morphological picture, as found in AD rats. Further, lowered concentration/phosphorylation levels of proteins thought to be the central events in AD pathophysiology, namely amyloid precursor protein, presenilin-1, Aβ1-42 and tau phosphorylated at Thr181, Ser396 and Ser202, were detected in 3xTg-AD mice treated with spa-water. The excitotoxicity-triggered oxidative and nitrosative stress was counteracted in 3xTg-AD mice, as indicated by the decreased levels of malondialdehyde and nitrites in the cerebral cortex. Hippocampus reduced activity of c-jun N-terminal kinases, extracellular signal-regulated kinases and p38, which have an established role not only in phosphorylation of tau protein but also in inflammation and apoptosis, was also found. Consistently, decrease in tumor necrosis factor-α level, up-regulation of Bcl-2, and down-regulation of BAX and the downstream executioner caspase-3, also occurred in the hippocampus of 3xTg-AD mice after treatment with Tabiano's spa-water, thus suggesting that it is also able to modulate inflammation and apoptosis. Our findings indicate that appropriate treatments with H2S donors and Tabiano's spa-waters, and may be other spa-waters rich in H2S content, might represent an innovative approach to slow down AD progression in humans by targeting multiple pathophysiological mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Brain hydrogen sulfide is severely decreased in Alzheimer's disease
Eto, K., Asada, T., Arima, K., Makifuchi, T., & Kimura, H. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00422-9 · Cited by 809
RetractedOttani, A., Giuliani, D., Mioni, C., Galantucci, M., Minutoli, L., Bitto, A., Altavilla, D., Zaffe, D., Botticelli, A. R., Squadrito, F., et al. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.140 · Cited by 70
Self-citationRetractedProtective effects of melanocortins on short-term changes in a rat model of traumatic brain injury*
Bitto, A., Polito, F., Irrera, N., Calò, M., Spaccapelo, L., Marini, H. R., Giuliani, D., Ottani, A., Rinaldi, M., Minutoli, L., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318236efde · Cited by 29
Self-citationRetractedTriple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Hydrogen sulphide and its therapeutic potential
Szabó, C. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2425 · Cited by 2,038
Cost of disorders of the brain in Europe 2010
Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.08.008 · Cited by 1,723
Amyloid-β and tau--a toxic pas de deux in Alzheimer’s disease
Ittner, L. M., & Götz, J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2967 · Cited by 1,269
Cost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wittchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,139
Apoptosis and Caspases in Neurodegenerative Diseases
Friedlander, R. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022366 · Cited by 873
Sanchez, P. E., Zhu, L., Verret, L., Vossel, K. A., Orr, A. G., Cirrito, J. R., Devidze, N., Ho, K., Yu, G.-Q., Palop, J. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121081109 · Cited by 638
Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease
D'Amelio, M., Cavallucci, V., Middei, S., Marchetti, C., Pacioni, S., Ferri, A., Diamantini, A., De Zio, D., Carrara, P., Battistini, L., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2709 · Cited by 572 · cited 1×
“, 2003); indeed, evidence indicates that synaptic dysfunction and cognitive impairment precede the brain occurrence of typical AD histopathological features (D’Amelio et al., 2011; Oddo et al., 2003).”
BackgroundHydrogen sulfide (H2S) - the third gas of interest for pharmacologists.
Łowicka, E., & Bełtowski, J. (2007) · PubMed · Cited by 557
The Alzheimer's disease Beta-secretase enzyme, BACE1
Cole, S. L., & Vassar, R. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-22 · Cited by 550
Hutchinson, E. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2985 · Cited by 532
Endogenous production of hydrogen sulfide in mammals
Kamoun, P. (2004) · Amino Acids · doi:10.1007/s00726-004-0072-x · Cited by 445
Targeting p38 MAPK pathway for the treatment of Alzheimer's disease
Munoz, L., & Ammit, A. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.11.010 · Cited by 369
Zipp, F., & Aktas, O. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.07.006 · Cited by 348
Traumatic brain injury: A risk factor for Alzheimer's disease
Sivanandam, T. M., & Thakur, M. K. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.02.013 · Cited by 326
Preclinical Alzheimer disease—the challenges ahead
Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291
Erdelmeier, I., Gérard-Monnier, D., Yadan, J.-C., & Chaudière, J. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970180z · Cited by 285
Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1–40)
Miguel-Hidalgo, J. J., Alvarez, X. A., Cacabelos, R., & Quack, G. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03731-9 · Cited by 265
Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease
Wang, J. M., Singh, C., Liu, L., Irwin, R. W., Chen, S., Chung, E. J., Thompson, R. F., & Brinton, R. D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001422107 · Cited by 264
Alzheimer's disease, a multifactorial disorder seeking multitherapies
Iqbal, K., & Grundke‐Iqbal, I. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.04.006 · Cited by 255
Bagheri, M., Joghataei, M.-T., Mohseni, S., & Roghani, M. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2010.12.001 · Cited by 245
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 230
Biomarkers of Alzheimer's disease
Craig-Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217
NADPH oxidases: novel therapeutic targets for neurodegenerative diseases
Gao, H.-M., Zhou, H., & Hong, J.-S. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.008 · Cited by 213
Xuan, A., Long, D., Li, J., Ji, W., Zhang, M., Hong, L., & Liu, J. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-202 · Cited by 210
Kida, K., Yamada, M., Tokuda, K., Marutani, E., Kakinohana, M., Kaneki, M., & Ichinose, F. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3671 · Cited by 191
Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases
Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y., Iqbal, K., Grundke‐Iqbal, I., & Gong, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05882.x · Cited by 173
Brain Insulin Signaling and Alzheimer's Disease: Current Evidence and Future Directions
Schiöth, H. B., Craft, S., Brooks, S. J., Frey, W. H., & Benedict, C. (2012) · Molecular Neurobiology · doi:10.1007/s12035-011-8229-6 · Cited by 168
Tau Mutations in Neurodegenerative Diseases
Wolfe, M. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.r800013200 · Cited by 168
Modulation of immune signalling by inhibitors of apoptosis
Beug, S. T., Cheung, H. H., LaCasse, E. C., & Korneluk, R. G. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.06.004 · Cited by 167
Hydrogen sulphide: novel opportunity for drug discovery
Martelli, A., Testai, L., Breschi, M. C., Blandizzi, C., Virdis, A., Taddei, S., & Calderone, V. (2012) · Medicinal Research Reviews · doi:10.1002/med.20234 · Cited by 163
Biomarkers in Alzheimer's disease drug development
Blennow, K. (2010) · Nature Medicine · doi:10.1038/nm.2221 · Cited by 162
Hydrogen sulfide and ischemia–reperfusion injury
Nicholson, C. K., & Calvert, J. W. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.06.002 · Cited by 158
Šalković‐Petrišić, M., Barilar, J. O., Brückner, M. K., Hoyer, S., Arendt, T., & Riederer, P. F. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0651-4 · Cited by 155
Giuliani, D., Mioni, C., Altavilla, D., Leone, S., Bazzani, C., Minutoli, L., Bitto, A., Cainazzo, M. M., Marini, H. R., Zaffe, D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0692 · Cited by 123
Self-citationKumar, A., Sharma, N., Gupta, A. K., Kalonia, H., & Mishra, J. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.050 · Cited by 100
Xq, L., Liu, X.-Q., Jiang, P., Huang, H., & Yan, Y. (2008) · PubMed · Cited by 85
Toxic Role of K+Channel Oxidation in Mammalian Brain
Cotella, D., Hernández-Enríquez, B., Wu, X., Li, R., Pan, Z., Leveille, J., Link, C. D., Oddo, S., & Sesti, F. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.6153-11.2012 · Cited by 80
Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease
Grünblatt, E., Hoyer, S., & Riederer, P. F. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0030-x · Cited by 64
Immunotherapy against amyloid pathology in Alzheimer's disease
Galimberti, D., Ghezzi, L., & Scarpini, E. A. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.12.013 · Cited by 58
Giuliani, D., Zaffe, D., Ottani, A., Spaccapelo, L., Galantucci, M., Minutoli, L., Bitto, A., Irrera, N., Contri, M. B., Altavilla, D., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0873-4 · Cited by 51
Self-citationOpportunities and challenges in developing Alzheimer disease therapeutics
Iqbal, K., & Grundke, I. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0878-z · Cited by 51
Neuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins
Giuliani, D., Ottani, A., Mioni, C., Bazzani, C., Galantucci, M., Minutoli, L., Bitto, A., Zaffe, D., Botticelli, A. R., Squadrito, F., et al. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.05.025 · Cited by 44
Self-citationCell and Gene Therapy in Alzheimer's Disease
Glat, M. J., & Offen, D. (2013) · Stem Cells and Development · doi:10.1089/scd.2012.0633 · Cited by 41
Profile for Amyloid-β and Tau Expression in Primary Cortical Cultures from 3xTg-AD Mice
Vale, C., Alonso, E., Rubiolo, J. A., Vieytes, M. R., LaFerla, F. M., Giménez‐Llort, L., & Botana, L. M. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9482-3 · Cited by 38
Melanocortins as potential therapeutic agents in severe hypoxic conditions
Giuliani, D., Minutoli, L., Ottani, A., Spaccapelo, L., Bitto, A., Galantucci, M., Altavilla, D., Squadrito, F., & Guarini, S. (2012) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2012.04.001 · Cited by 36
Self-citationGiuliani, D., Ottani, A., Minutoli, L., Stefano, V. D., Galantucci, M., Bitto, A., Zaffe, D., Altavilla, D., Botticelli, A. R., Squadrito, F., et al. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.03.009 · Cited by 35
Self-citationAnalysis of Human Tau in Cerebrospinal Fluid
Hanisch, K., Soininen, H., Alafuzoff, I., & Hoffmann, R. (2010) · Journal of Proteome Research · doi:10.1021/pr901002t · Cited by 17 · cited 1×
“In particular, tau hyperphosphorylation at sites Thr181, Ser396 and Ser202 has been repeatedly investigated, also in 3xTg-AD mice (Craig-Schapiro et al., 2009; Hanisch et al., 2010; Oddo et al., 2003; Yu et al., 2009).”
Background
Cited by
Chemical Biology of H2S Signaling through Persulfidation
Filipovic, M. R., Zivanovic, J., Alvarez, B., & Banerjee, R. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00205 · Cited by 1,046
Lin, V. S., Chen, W., Xian, M., & Chang, C. J. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00298a · Cited by 1,037
Szabo, C., & Papapetropoulos, A. (2017) · Pharmacological Reviews · doi:10.1124/pr.117.014050 · Cited by 423
c-Jun N-terminal Kinase (JNK) Signaling as a Therapeutic Target for Alzheimer’s Disease
Yarza, R., Vela, S., Solas, M., & Ramirez, M. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00321 · Cited by 410
Zeng, S., Liu, X., Kafuti, Y. S., Kim, H., Wang, J., Peng, X., Li, H., & Yoon, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00799a · Cited by 341
Metadata
- Authors
- Giuliani, D., Ottani, A., Zaffe, D., Galantucci, M., Strinati, F., Lodi, R., & Guarini, S.
- Venue
- Neurobiology of Learning and Memory
- Publisher
- Elsevier BV
- Published
- 2013-09
- Volume
- 104
- Pages
- 82-91
- ISSN
- 1074-7427 (ISSN-L)
- OpenAlex
- W2070478570
- Cited by
- 254
- References
- 51
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.